Drugs / CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05060796 | Sep 2019 → Nov 2029 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04153799 | Nov 2019 → Dec 2021 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04153799 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor Autologous T cells” NCT04153799 ↗ |
| Route | Intravenous | “intravenous infusion” NCT04153799 ↗ |
| Target | EGFR | “Anti- Epidermal growth factor receptor(EGFR) Chimeric Antigen Receptor(CAR) T cells” NCT04153799 ↗ |